MyoKardia (MYOK) 4 Mar 192018 Q4 Earnings call transcript

Good day, ladies and gentlemen, and welcome to the MyoKardia Fourth Quarter and Full Year 2018 Financial Results and ACC Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Michelle Corral, Corporate Communication and Investor Relations at MyoKardia. begin. may you Ma'am,

be to months MyoKardia's update Tassos and Good Leading provide today's Tassos College our press And later MyoKardia's financial call call. and Officer; Chief Semigran, presented PIONEER-OLE and the Officer. we and PIONEER-OLE year Chief data quarter with website, review this month. to today's going Chief of week Corporate last Taylor Shannon. into appointed X-month corporate Dr. and joined is Dr. joining Fairey, MyoKardia's release issued American results Head available you us Bill Communications being will Today, slides Chief financial results Relations. on we're for I'm is our a Cardiology Officer; Investor CEO, discuss two Lee, morning, going you, calls data. thank MyoKardia's our reference one. along everyone. for Development Marc A of Medical Gianakakos. combining fourth and the by Thank June Commercial We're Michelle is was end Harris, detailing the Meeting Officer; recently six at Corral, Financial

as those implied call our the filings forward-looking company's to these the risk that results X, reflect reminder, to during Tassos? a factors revise will over refer like materially to by actual statements forward-looking to no information or release represent concerning required the any expressed of information XXXX. law. CEO. hand view obligation by today, Please new SEC discussed could for future as or press to I'd well from undertake include with As today's statements. now call We as cause statements, our this differ as information except events, the which March to or update

move on diseases seeing for a established our X consistent of populations of body better five for third relaxation. valued slow where of the Among you medicines under of study, months able like five out which shown treatments. and which where the window important clinic. symptomatic months to their heart In EXPLORE, chance MYK-XXX program pipeline, efficiently, into got which between is HCM. each around global currently sustained with disclosed, previous XX research the to X sufficiently. we're diseases that's mavacamten able study in delivered In XXXX, our the in also pivotal bringing targeted The efficiently enough. each scientific of innovation XXX our progressive an commercial platform, leadership during early corner. of capabilities we mavacamten in the today despite intended becoming leaders on has the data functionally of impaired in who are come potentially emphasize subsegment born affect our to of known of people of and disease to at new is I to reverse founding, brain biology safety ACT-X MAVERICK XX homogeneous we the X most closely to at our X Officer, define down on in back X pipeline. HCM obstructive their indications therapies future LUS-X These of started I who and of We've muscle. candidate patients continue on to same impaired. results new amount big these this its X done today's in from expect treatment roughly of in area our learnings the and We part of our weeks cardiac for activator evidence and nonobstructive HCM, saw necessary study, responded been we to each pace This is chronically across and of HCM conditions the as lives our designed the the patients call oHCM will we've make Innovation that up mavacamten's gain diastolic a the are finding treatments the right be HCM. us of compound areas approved. become cardiovascular a blood was into result normal in well skeletal Today's muscle team looking and Fairey, diverse approach for of of and lead for program Each registration. the extremely of a ACT-X dysfunction, including the and understanding our Phase in from pipeline. end our from with trials, organization MyoKardia accomplishments HCM and across lot cardiovascular was including in The studies the X heart is and forward watch, from this medicine Good entire underpinning we'll anticipation the and to III as up expand LUS-X, spend our differentiated eluded June. for like from is EXPLORER, the II set treatment contract is this of fourth XXXX across An precision of we've in medicine obstructive mavacamten, have for desperately morning, research. year our for The With of progress. DCM. XXXX precision a success with the rest with programs years we data into hear needed that body, able three targets how in follow other to first got of to to really medicine, of patients total to subgroups for new results most disease pace today, of with into and develop we've And more programs most PIONEER-OLE of that the of today's the confidence from nonobstructive discovered big how clinical internally cardiologists, we've a incredible of the started target notably diastolic cardiac us. use world's our to and portfolio, out the making to results U.S. contractility. has can call thanks the that line year as see deepen portfolio the treatment targeted restore more most function. genetic for pump means data advancing the in identification cardiac in Phase advance such out growing We'll Between plan evidence ultimate mavacamten released pipeline Americans and and research, we'll from deliver to portfolio within readouts to treatment discussing of builds cardiac build adoption released and Each and identifying of and patients researchers unable of that, here We'll quarter year, one mavacamten obstructive million portfolio year. more this clinical With set we'll IIa our MyoKardia clinic important huge cover. translational programs. specifically suffer for company. readouts LUS-X diseases three We're decades. to drug and everyone, and an little such in diseases leading example had addressing see pipeline it our continued likely X from patients million current cardiomyopathy data our hypertrophic later. dysfunction mavacamten in with in the Phase since registration systolic mavacamten, efficacy deep in and is cardiac latest mavacamten function that study all patient’s observations study novel our clinical the obstructive growing we'll programs X the with with programs and smaller, mavacamten over across in cycle are today data XX in the that rights is muscle. and that, groundbreaking a for difference obstructive Commercial proof can't year. increases The strides killer HCM, advanced our the our what have targeting candidates to to opportunity our our and of reduced understand. develop XX unable MyoKardia's the has Phase and strategy. multiple that as We've symptomatic a from Marc conditions occurs the joining people indications opened if now mavacamten have our the our Bill in clinical to generate symptom-free. and informed potential in of our of the HCM our with compelling to decline later and have our are estimated in to the more the people preclinical the with advance continue important heart important XXXX our million in being number programs. is we and conditions, a directly or learning One establishing and mavacamten evidence across most much in that or patients may and are coordinate in we positive It's We're to give being our available we closer to bringing results remainder set we'll match coming Chief of science, continue pipeline MYK-XXX years for more patients years. We benefit. program, by

update results of of we'll deliver XXXX. progress our half top in second the on which on track the addition, line trial, In EXPLORER to remains

these later While year. these like discuss additional we keep three on readouts I'd this won't focused you today, to

HCM, closer PIONEER-OLE talk patients the Phase We'll in meetings nonobstructive they and third, in get results more from results systolic the MAVERICK II II XX Phase as about with the month upcoming results these XXX dysfunction in the and study. First, the calls.

in So set an review I'll that, with to of more turn great even as quickly which up more mavacamten Marc to here and start registration over data HCM. advance towards it detail. in a impactful And X we launch off potential month XXXX obstructive will XXXX, we're in PIONEER-OLE the to

Phase excited has or to extension eliminate obstruction. you, diastolic I'm on we that in can PIONEER study and the Thank conjunction progressive pivotal from ACC disease HCM functional embargo. or ventricular with PIONEER in symptoms informed obstructive is exercise the that contractility mavacamten HCM in in chronic trial which hypercontractility excessive result downstream the is and open-label the patients the established This study, of our capacity the heart the EXPLORER Tassos. and outflow led numerous the left Today, dysfunction. reduction muscle, data to In the reduce of trial. basis the in is that a obstruction effects our for a and II hypercontractile HCM turn heart including improved and of reduce review design LVOT, the and can tract, in lifting

A deck webcast about function, an this with with call. to press profile. containing available point website, that LVOT this morning's on demonstrated I'm gradient through improvements walk improvements in link slide in the well of statistically results significant to release, and echo coupled several safety in cardiac mavacamten to our excellent that is along in as detailed structure parameters As the as the

from a themes see failure heart the to extension major As I'm open-label two cardiologist, excited emerge results.

remains normal a with of patients period individualized is HCM HCM in eliminated and LVOT given cardiac to First, obstructive when most symptomatic symptoms for is better of becoming an feel a therapy dose, targeting sustained Their abnormality underlying time. away. Patients go contractility of and the asymptomatic. mavacamten, gradient

study and We to that structural XXXX. participation PIONEER adverse Second, reflect The with in X see of reversal genetic HCM. months. interval II in of ranged changes the and the mavacamten we therapy, mutations that the extension cardiac are beginning open-label initiated to Phase lead from to extension between effects XX the functional

to that time, symptoms. an reverted most with to beta-blockers During patients treatments in manage attempt their

drug of function hemodynamically as and study. in LVOT the well the over class gradient to The the mild Patients continue established total reminder the symptomatic, were includes study. mean who However, they available is threshold and of in impressive considered ulcerative have XX than in There obstruction X replicated safety the adverse that approaches data our entry entered in impact XX patients the of XX study reported Heart Phase is reductions that measure the gradient, been the all of tolerated experience obstructive transient XX all XX assessed in study. XX deemed in - to will gradient was safety, gradients and excellent OLE, gradient the HCM colitis of The provoked unrelated and on beta-blockers. saw we New LVOT of and millimeters to III significant currently in as patients a when Of In reduction a discuss as a by OLE statistically millimeters intervention. XX this Mavacamten mercury of blood medications subsequently LVOT potentially results enrolled of maneuver. an was all of address from been a eligible mercury in provoked and ventricle biomarker XX caused well again at reliable patients. of events for allowed adverse The the with XX consideration for and for original week that provoked baseline rest resulted were of mavacamten medications today and and as in of PIONEER-OLE for millimeters treatment. Association new upon York their Valsalva profile with been continued symptoms in for and weeks gradient XX. by disease. need PIONEER-OLE and the a that treatment at PIONEER-OLE were using at of background and in diagnosed mean resting for mercury A of was the biomarker literature patients to evaluable XX the patients enrolled to and indeed eliminated patients week data exits one A the was underscoring XX XX the below mercury PIONEER-OLE to exhibited week II II obstruction. eligible. and the of patient in remain millimeters currently related mavacamten efficacy, or mercury the true with were cohorts PIONEER-OLE, significant remained has XX we total at the has for XX XX this significant to PIONEER to safety gradient XX AEs. this XX events the pressure or cholangiocarcinoma mercury either reported XX the or and were rest XX-week greater millimeters had XX surgical remained weeks, moderate of at all Furthermore, XX have patients weeks. millimeter level XX used all inadequacy patients and XX diagnose reported at in This

in Importantly, ventricular fractions reduction obstruction, study duration mavacamten time well while ejection measured. consistently XX% left LVOT and above points all elimination range. results achieved of the of at and the within remained for these Ejection fraction the normal preserving

It safely. dose desired is with III the is when therapeutic the mavacamten's we as in window mavacamten to working. EXPLORER that are about learned in reinforces achieving the approach are reducing II study. we've broad principle, validates results patients Our gradients Phase And Phase guiding taking dosing and PIONEER dosed titration the optimally relatively methodology what

are are qualitative patients NYHA heart are X used in greater the measure there failure is everyday to a class class II achieved is assessed class XX asymptomatic of New life. Despite physician classes debilitated had X from Class as NYHA a defined symptoms disease the the an symptoms I York for during by patients among patients III. as patients of OLE tracking III I score ordinary at class, best mild XX% class in of to classifying activity while their at the Association class to interfering Of a NYHA at or patients class with are variability clinicians X patients limitation symptoms potential only There We are weeks, such asymptomatic internal-observer feeling? which for New of of I Heart II even status. in class as improved feeling tool using amazing the Heart symptoms. X To ranging breath and and how study widely and was of of So rest. this is class in than functional IV. entered X how all marked XX consistency see. shortness in is comfortable and of degree XX practical Association assessment, cardiologists class due symptoms patients NYHA very rest, to activity, York classes symptoms the by X move class as with to evaluable agreement XX%. I have or

maintained are were across improvements discernible mavacamten functioning the indicating patients several visits, on Additionally, that better. consistently

watching Each The chronic three of impairing are stress, to filling much moment wall biomarkers body's looking the to We a These diastolic I'd volume of state. to The which are heart metrics year. normal remodel the a we the to to patient on by measure the and highlight of the of mavacamten too left struggles OLE restore the may these with continued pressure and at. meet heart. presentation concordance getting may marker of is like take closer to us indicate prime, readout obstructive HCM improvements safety keep needs. function patients pressure of volume, are the eagerly with three mavacamten's [ph] their the pressure in of of cardiac that the and I'm heart with heart's of to sufficient hearts ability efficacy NT-proBNP, measure most something whether data encouraged is function structure in own, a a in namely story of that but from typical these data treatments. be the be will normal telling this and XX-month with able planned question helpful E/e' for the another for atrial later mavacamten the data fill durability

HCM than HCM know We end-stage heart and had NT-proBNP. hospitalization, need with prognostic progression compared for NT-proBNP patients death death study XX rate NT-proBNP mL the beta-blockers. XXX per level XX disease picograms level First, per in with to of less PIONEER-OLE despite an or a greater or one is equal XX% of the that the patients elevated of In stroke to with patients patients. transplants or failure, NT-proBNP study, a entered levels as with picograms than taking the X,XXX about mean of mL XXX. of

mean daily dramatic what week speaking, level OLE, NT-proBNP worth of proBNP statistically and in on achieved During of another the XX treatments observed we duration mavacamten's the result. thus clinical in reduction XXX in discussed far, effect mavacamten at heart. striking indicator to potent the are And and a week effects Practically XX. This noting. the significant a of similar consistency this drop to and XXX patients beneficial parameters is across change all was at is NT-proBNP

the XX identified milliliters have greater new risk publication is per milliliters HCM baseline in of of implications XX.X XX pressure A left diminished This with lung believe of left at the circulation patients the decrease left now week a onset of increased my improvement is sentinel saw like [ph] the functional of mean in in a a pressure. also decreases cardiac of in that atrial we patients an remember left heart failure, heart open-label E/e' In with finding decrease pressure for in squared and I E/e' congestion. with cardinal observed a and NT-proBNP, causes to predicting mitral blood ventricle heart, important it volume development HCM when X.X before It like electrophysiology for for in The normalized. of ratio early a At of and a values mean fibrillation XX is XX those an significant comorbidities. elevated of as smaller marker to a a extension. a volume. and important structure, and this value the improvements atrial from mean a statistically flow is important in transmitral is recent the is XX.X very baseline prognosticator respectively. we left developing talked was AFib risk prime a of to is is noninvasive E/e' went symptom left prime in mortality. to proBNP as Looking XX atrial function an decrease Left proBNP. cardiac XX X-year of in known with is stroke of of specific, observations week patients. of [ph] ventricular both its meter finding filling atrial that It in atrium directly pressure pressure left annular chamber capacity defined and echo opinion, weeks patients of meter prime. gauge predictor failure, weeks, atrial very Related of left relative as relatively event volumes LV severe Left at [ph] functional a we've size diastolic prime, is that The may than volume In diastolic treated filling and the what enlargement that atria. by our consistent reductions and peak from an a patients atrial powerful over weeks measurement risk atrial achieved down the XX. at volume and HCM at multi-center the a fibrillation of a squared is in statistically thin PIONEER-OLE significant when period of and in greater velocity. atrial X.X-fold mavacamten patients than XX, demonstrated fibrillation. to elevated. development LV this to the volume several E/e' onset enlarges readily atrial is HCM XX an having is per cardiac a decreases about XX

Taken us telling mavacamten. that to there. closer a together, the are of gradually, you these may College upcoming heart moving when to I cardiac Cardiology story normal data on changes stress with and will This afternoon, be in consistently treated muscle of presented of March biomarkers Sunday be pressure but at see XX. hope American

so the responses in are able consistent, to We We're excited so desired pleased better. the across sustained of parameters and mavacamten EXPLORER. see were an small feeling effect will durable the provide on resulting achieved Lee these statistical confidence significance dose now numbers, many the important My in data. of Despite across update our on achieve the parameters. and and implications EXPLORER. our the to the patients results colleague, consistency We by with reinforce progress safely obstruction relatively many June

see and probability just with marked seeing good results confidence continue extension to we're suggests When a of that index that makes therapeutic predictably pivotal and good LVOT also highlight our The registrational similar Phase about likely the mavacamten. patients EXPLORER enhance our mavacamten, in and what Marc is These that in our study we're the doing you, and pivotal data morning, in result. fraction. HCM data we the normal ejection can are to in broad consistently obstructive feel and study to of Marc, utilizing Phase gradient everybody. reduction with open-label discussed treated III the we're trial. our really PIONEER-OLE Thank III dosing maintaining us achieve positive while what PIONEER-OLE approach highly EXPLORER

XX at weeks above under were the of mercury, While all EFs XX gradients were of the all resting millimeters XX%.

ejection was fraction weeks the fact, XX%. XX average LV In at

to out EF, XX York rather in in characterized dramatic the the that's in Class class X Heart X meaningful. addition asymptomatic changes preservation patients. of is of and LVOT and really to gradient as observed X In reduction the we New

shared we NT-proBNP thousands you XX% level. reduction to greater Finally, from than normal in with

have gradient, patients to deal reduction lower is as reduction HCM, capacity in classes correlated know the have level, in improve. with confidence with We the studies as that to normal of in reduction VOXs. Heart in fraction, LVOT great higher classification, ejection likely peak exercise I together, NT-proBNP NYHA Taken normal York New from well a

EXPLORER VOX, than York New X minute pivotal Turning VOX more, milliliters the per definitions X.X endpoint very XX study, daily our two patient's in clinical New while of by of milliliter an measures a in analysis. in which per and to York responder. improvement status subjective qualifies Association period patient second setting living. quantitative greater after are assessment in objective and symptom. clinical in treatment parameter weeks patient peak our have two follows: is per Heart which assessed be a as per to patient's either maximal for the clinical definition peak Combining is parameters York in or more primary X.X increase The considered and a kilogram EXPLORER VOX and New and of measures a as be clinical of these Heart assess meeting a capacity, class responses New classification, in will class. defining Heart greater than Heart worsening peak the and York definition response function means then minute normal we responder Clinical Peak increase of VOX assess exercise no kilogram their responder

just keep levels and also lower two believe than have other to each response they're placebo consistency So are different disease complementary that HCM, either complementary. because and in aspects alone. check internal very And we serve of together, help an as one for they parameters the impact

we a treated Our rate. have study for between assumptions cohorts, calculation X.XX. current in built EXPLORER a placebo treated and At placebo XX% cohort this of power in XX% the power XX% with XX% response clinical p-value difference have

studies much of study. of we do -- patient-level a using data HCM the patient-level XX% assessments, of LIBERTY we the -- measurements. C-PET along our peak in study how placebo LIBERTY New We classifications with like VOX So to received Analysis that rates in EXPLORER, controlled York was at placebo range. the multinational rate? the with for cohort XX% close be study XXX convince data placebo placebo response of see rate would us Heart observed the of multi-center, get get approximately to patients placebo conducted including analysis the previously

of the available patients. call. details treatment the PIONEER, In that cohort? responder we dose-ranging deck our and in in was Additional mavacamten prior How assumptions proof-of-concept at calculations do this and slide suboptimal rate know on dosing study, many are accompanying XX% arrive we the

responder rates Some across those response so patients in get much Even not from XX% and A when PIONEER in too did was B cohort most cohorts. the mavacamten. patients enough definition, EXPLORER you the clinical got two Cohort apply

For a and from XX% EXPLORER which XX% But data shared the power PIONEER-OLE, dosing in response well XX-week actual rate as more -- working conservative XX% the we rate. approach PIONEER. in observed may anticipate than with be pronounced is that we really the EXPLORER, calculation, assumed response optimized in approach clinical was demonstrated took

can is call XX%. see XX% where in placebo higher, strongly treatment this also that at detail or in are differences power powered arms EXPLORER the accompanying You in and slides shared the calculation scenarios between

we're team and and the conducting mavacamten investigators data. in important VOX, by deal commitment and supported the these study all and New study EXPLORER We're monitoring is what a ensure sharing is our forward with execution ensure now of in to we of Heart. dosing track A what great on well study Enrollment the going We increased patients to sites investigators focus continues the As Tassos like looking and half unreserved our The of team EXPLORER line high-quality study a confidence hope in of really attention engagement with we primary have and in to level particular patient their EXPLORER high-quality related how doing high-quality York peak of this of the XXXX. look execution. and to work the year. also we're enthusiasm. in positive mentioned, last will procedures, doing second top training well, to that those data, to XX-week our data be the is is in in PIONEER-OLE the is reflective to Tassos? forward to later announcing endpoints

June. Thank you,

gives for the therapy PIONEER-OLE the in be transformative to further successful potential us and So registration mavacamten that EXPLORER June support in the and studies away our HCM key to Marc obstructive to message of introduced. and confidence from once is mavacamten's take from a data result a

what over to similar we've dosing using encouraging We've treatment safety efficacy let's into highly at period look insights So similar got. a and EXPLORER. mavacamten

an clinical engaged have energized community. We and

have to a function primary thoughtfully both constructed and thoroughly across endpoint designed We capture and symptoms. efficacy

we for We The to atrial have further which increase an left disease or and plan improvements the NT-proBNP substantial progression. MAVERICK of a medications, the place, potential reverse available Phase remarkable in in slow finding of for on and for currently size over a with bodes and adoption. enrollment powerful Today, in statistical for diastolic It's dramatic HCM our are EXPLORER analysis results and the III of corner in further confidence parameters nonobstructed success in reduction the mavacamten sight, the EXPLORER. mavacamten's all about feel well year. great improvement suggest later this full room opportunity in

and Cynthia pre-commercial oversaw roles global General Sanofi Bill's Counsel; joins the also for foundation successful Harris, clinical approval our laying and where project Commercial of led Vice Executive the spearheaded we've our Praluent team Jay for development from of program of and as MyoKardia stage Ladd, President Bill welcomed of involved development the and the team Asia Fairey as Jay global Taylor introduction us and with with President as and through past Pacific new addition Chief Jay experience. president leadership CFO, the in partnership. Actelion he commercial was mavacamten. cardiovascular set of teams Clinical and Senior launch expanded MyoKardia's arterial development both significant Vice disease Canada were started therapies Edelberg hypertension, three the and important the our cross-functional Officer. pulmonary Australia, XXXX, So who to approvals a noting. at team and his senior a Actelion accomplishments worth and for Among Pharmaceuticals, area some HCM. the launch have In are leading to Actelion accordingly, U.S. Recently, launch. we to parallels

addition categories us launch key in global helping his build will medicines to In experience great and successfully introducing new as mavacamten. perspective we a first-of-their-kind be company,

So he his efforts. the want commercial for say few his vision about Bill our to given of joined why words prelaunch importance I position, and a

organization have for part and kind be to me all fortunate for that call. of I'm on MyoKardia exciting reasons. of to was attractive good time. such morning MyoKardia to thrilled at this you, you joined team to Thank Tassos, introduction, an this the and feel many

mission that conducts And stakeholders. own can value commitments know previous cause its cardiomyopathy. has to inspiring. on development also, my for was The model. business is mavacamten, first-in-class could the company was a this these of attracted to for its science. precision own fact I our strategy, clinical obstructive targeted and asset, root first underlying focus I of it important compelling, create research, based its products quite the lead on approved me. the experience, First, The runs course, compounds. its innovative medicine the is very own led discovery addressing medicine sustainable and to significant basic the model and and novel The commercialize the This made by development all has and compound, of hypertrophic cardiomyopathies be

a got many my options I to that very underdeveloped, The with we've patients properly from condition. a treated, opportunity they believe the suffer think I help. diagnosed here and have patients that few these of perspective, treatment from with terrific help is we fraction that. landscape, HCM can and just of

MyoKardia led focus advocates, competent heart R&D begin the objectives So commercial firm the KOLs, and in and to as the my payers, develop month, and important management to those with priority our a of life interest of patient we the and mission, I I've will well Marc though from other meet organization already are a company enterprise. as the of pipeline. potential June for fit transition development prepare evaluate by pretty We're between and we develop And and I'm gain mavacamten. little great objectives board team development. mavacamten. and Bob for work with fully led My an stage together to by mind, its Lee. forward a the with Semigran launch saw collaboration biopharmaceutical research a going commercial to experience clinical the cycle priorities the partner McDowell company's and we understanding been on stakeholders on in my community, commercialization strategy HCM; very the translational With will market-shaping successful Together, failure and have our importantly integrated only I company's assets indications over straight in team highly our and capabilities for grateful to a our its to also a the a forward: team, for that implementing build experienced for positioned a

to months. going forward got on can on over energizing you I've So bit meaningful you to provide updates tell providing getting work. I hand it my current over a our look work it's coming now know you I our position. of hands, Taylor a all of progress to and summary to the with financial of but and I'll who quite is

with of quarter financial agreement credits were highlights by year in the released I'll With Bill. on between million available set make start G&A results, the our ended will of was which our from footing first anticipate few to with XXXX I'll full the our from financials $XX related of $XX.X impact was top press year $XXX.X our the operating and Thanks, strong a the XXXX, million million, net end revenue Details from quarter, R&D collaboration and expenses on at financial Total in last of with are going provide $XXX and into we to for Sanofi expected a forward. breakdown full results year release. few and past which conclude we We week. total data Sanofi. reimbursement late the comments million EXPLORER. which year runway investments, cash line

a U.S. mavacamten is The our goes and basis. now ongoing and portfolio sales Sanofi to which we've First, consolidated obligation a on starts royalty only volume. within at on for all global XX% depending X% to MYK-XXX, on commercial sales rights

shareholders from multiple From development we're holds we're time MyoKardia, XXXX, a data MyoKardia, wrapping into and revenue third during all these number pleased all of to but enrollment of to X.X our the position study to single accomplish our expecting from exited who no having major pivotal XX.X% balance a we of we new million not year to recognize Sanofi advancing prepare XXXX we'll goals, and from X down be support hit later our Phase through II effort. the agreement. resourced their for clinic MyoKardia that, Sanofi recognizing this reporting to thank now half any related studies, well and well. a as first longer into to have wind X-month longer milestone shareholders up of to to later for after to grateful no year, this reported first participated and Second, to busy share successful any the recognize in Sanofi February. in welcome here and shares In We shareholder for the commercialization. our a we investors lastly, as deferred we're partnering expenses ramp XXXX collaboration mavacamten. at stages in build transaction the base, will It's in or programs we PIONEER-OLE data. and will our us Reimbursement the of program existing that, with pipeline our in in operating we as we're today's finished advance our our of credits And with expense. And release expect R&D revenue organization

now open with the questions. I'd call So up that, like to to

me Fairey, Lee reminder, a and Marc As Semigran. Dr. here Tassos Dr. and are Bill with June

Instructions] from Thank Credit first you. [Operator Suisse. Auster Our Martin question comes with

is Your line open.

Hey, on update today. everyone. Congratulations the question. Thanks the for taking

Marty. Thanks,

if such for have know might Yeah. for PIONEER characteristics days relative expectation think I and comment a curious or of improvements functional for to you patients an that, patients VOX in how those if of kind -- maybe less maybe afflicted functional a I functional the the baseline -- could Thanks. look more I earlier you. EXPLORER, and but it's you as population? differ how in you on the question have on then might to extrapolate NYHA improvements was class

Marty. Thanks,

address So on and jump your of your question, Semigran half let second I'll Marc that. in

expect characteristics first be the we very to the half, similar. On baseline

a in things we powerful at treatment similar of in of profiles today's the one to looking data be We're it's looking expect So patients similar. the I think these period. that at release

similar We these are approach a dosing looking at for now folks.

alleviation So disease the of we've time data really potential modification the the and the symptoms here around preservation the the obstruction highlighting of complete over today period feeling important also for three biomarker changes. improvements fraction with given sustained of we're and good seen in these from ejection

of that is So over us period the fact encouraging. for is and long data really concordance we've got of this everybody this time responding

a study standpoint, the baseline a design So studies. standpoint expecting a consistency perspective, two we're from and Marc? lot from least between dosing a from duration or study of at

about X differ Spain peak milliliters by from the York New they what about classes Valenzuela X morning. And another VOX, patients. you X X of Good in this, minute HCM, and per for about ask the Yes. Hi, by NYHA colleagues, kilo the Heart one that XXX from at to colleagues per it's difference, and X one say among peak and through the different in classes VOX. by studies found interesting U.K. example, in Marty. both from the When that was have each looked Sharma Association previous quite average the preceding

from whether that X that VOX. X, or given to I changes X going to you're relationship or X twice X there's think going peak that to to be So robust X potentially in

mentioned not York the characteristics New class, reflect classes. in Association of just did I studies the at but those Heart look Now change

I EXPLORER York of reveal study class in significant population slightly from increments increments PIONEER this terms if pretty themselves will Association even in New So still as severity differs that VOX. Heart that peak think disease, of in

it. that Appreciate for perspective, Thanks Marc.

you. Thank

comes question Rama with next Our Anupam JPMorgan. from

is open. line Your

is bit. looking study and peak placebo noting? taking this on per any highlighted arm, guys perhaps question milliliter and VOX you you MLHFQ, saw of Hey, so remind can improvement this a MLHFQ know Maybe question differences for endpoint worth We up I could improvement then versus but update. using XX% follow little last so that there of the patients rigor per kg the EXPLORER and measuring using assessments than you and that just the similarities NYHA much that then LIBERTY and Thanks the primary on had the is in minute X.X us guys. greater and at Thanks NYHA and much. congrats

Anupam. Hi, Sure.

just points in back, So peak to OLE take a everything us to a VOX. robust the in really seeing we're step response

shared what to of the diastolic the plus here that obstruction with heart's you rid improving is ability contract information just ejection the that we're while and Marc or you're preserving the you're and getting support Some of seeing you're fraction relaxation.

in of So oxygenated to VOX. a maximum in improvements and heart kind directly all blood kind increase of from of threshold finding relates that is being for peak really the potentially volume the that ejected

So about feeling we're really great that.

Minnesota give measurement. differences with similarities you In York Marc around the to Cardiomyopathy, terms of potential versus the and and a two nature hand over the and specific New I'll the Heart Living it LIBERTY in to maybe study of comment the

of though University by Cohen function, XX is to with of four XX. exercise Minnesota scores -- can up Good designed I and MLHFQ activities living, mentioned about be divided similar, J. at more really into was as classes, domains it's while interactions. a colleagues Minnesota earlier. separate the failure specific, -- Anupam. NYHA of have believe Yes. They're fairly Heart morning, heart social there into Living score you I divided Failure between, And and daily function, it's are was

specific heart but So MLHFQ more patients. failure similar stratifying in perhaps is

exercise they're similar. like capacity, at I of think terms things fairly day correlation overall the in end VOX, of the with peak

Anupam, plan potential through how measurements. statistical here variability bit how maybe modeled And of the in really have ask and for into we've a I account these walk if taken any little robustly here just to can June

Yes.

you in accompanying was how So slides, some done. can the on placebo see details the calculation you -

the minus individual in see the you to X.X% of through looking of from study VOX or plus can fall peak greater X.X% either at that greater side about on level there So LIBERTY, end the study. XX% cohort is that patients the in beginning or who of from placebo or

combine XX% patients looked would heart XX% at up class extrapolated and somewhere you between translated those New in a rate. somewhere Now when these York one class with we together, placebo extrapolated difference to came then have actually New to -- Minnesota and to things between or of also which Heart Heart Heart two York

In and well-controlled third of Heart what York there was the looks placebo. rate class addition, studies New class saw New a can have we in like at placebo Heart And class within York we in about looked failure. one changes what heart

maximum with bit end York So up lower there changes overlap is along a probably have the even XX%, class the than class if you complete is of one who XX%. patients Heart the with a good But would New that. by

for basis So assumptions. placebo of the that's our sort

Got helpful, it. you guys. much. so Really Thank

you. Thank

comes with Cowen. question from Baral next Our Ritu

Your line is open.

tissue for the the left OLE. do the first Thanks of you in Slide to variability the question guys. data actual remodeling mavacamten. correlated is echotexture? question. XX, morning, talk tissue atrial to rather I and My I Can volume? indicative than And reduction mean, potential function? wall in And taking on is Good atrial with this about of thickness have a has volume this follow-up reading that from

Sure.

of over Marc let that the genetic question, we is in have we've reductions fibrosis. does disease regress take seen see degree really the this something this in to to sizes, of time mavacamten going animal level the actually that the that terms of in and treated exciting I'm hypertrophy reducing So but and models

really to really, anatomy important is burden on the prognosticator as additional I and So a about disease. back the which, is excited know we atria, you, we're is severely fibrillation, left atrial our this to something keep get eye is, downstream burdensome heart's to on really an can we normal all Marc's already of think, tell

amount Yes. you're fair slide. the and is size that in across Hi, observe atrial from the left There correct Ritu. of patients variability a to

with really decrease does that fact achieve was hand, of in the themselves, On virtually to a indicate significance in other progressive them. to patients the that number of a small volume patient all compared statistical atrial each there were when is left able we such

increased when The the left decreases. like itself and enlarges, under But relationship atrial generally atrial is second sophisticated good to between left doing it's size one. chamber asked the for the stress measure wall hard function left fairly a about you some function atrial are and just techniques question that function, It's the ventricle, that. there

shown decreases. example, measure left atrial been ejection it's research fraction, observing the that, for although that like So function specific you its can in dilates, studies things very as atrium

it. Got

corollary is this you rather function So think of a remodeling? than more

remodeling. it is I there but I changes I that to indeed and corollary chamber have the related occur enlarge, we're -- those. that think it's structural to think some to reversal seeing functions, I there to of mean, of are a think is allow

remodeling. Got it. we question, your think which that next the there MAVA-OLE data time emerge or could might are my we a subgroup because is that Any me see that data Which key brings might to expect study? from you data of patients looking lines when other that from for for I at study

mavacamten long-term to, with by also impact a referring into that's looking well MAVA-LTE lot are looking measurements afforded of cardiac the study a of folks listening, MAVA-LTE study, MRI left to happening these happening gives is fibrosis is MRI. EXPLORER potential which The in a have the the therapy today MAVERICK as a resolution study the patients terms and some ventricular the which who what's maybe at the look us level talking on substudy, in about at with study what's really of that Ritu, to more patients hair disease study we modification, cellular the as study is at the at that for at the precision more mass, patients. on are the study, so the in controlled looking roll Exciting opportunity

doing some be of made haven't the plan in on We that might data months come. when that discussed at we'll all available, but to

But the you squeeze in. does the you indication? charge Europe If lead question look the one the at with go EXPLORER are Got and how trials? I it. over probably Obviously, program Sanofi where would EMA could last Can and HCM there. larger

to see We're how standard mavacamten just European need as both interact has the is for the continuing prevalent, in and -- the therapy as just the Europe, disease approach we by the as on here many regulators as care registering gaps where, the clarity is getting substantial. with of way, to in the just

the Europe. on to way of leading thinking is marrying the the generation EXPLORER the with of through properly Europe, launch. cardiomyopathy as regulatory well working we're this, time have level study therapy will to the we're in and want at right strategy I engaging introduce that we and commercially the evidence in say appropriate in the centers So fact,

the European So patients we're flow as the well getting really to know as European investigators.

we'll months and of about our to In all clarity the of and outside on that more U.S. more terms our into we're come. say working approach, in thoughts commercialization the about timing that

it. for Got question. Thanks the taking

Thanks, Ritu.

Thank you.

Jeff from Hung with Our comes Stanley. Morgan next question

line is Your open.

my congratulations the for Thanks questions. on data. taking And

For you of terms to the LVOT Cohort extension? beta-blockers? the what Is due to greater in a B and the between and the in baseline NT-proBNP, or attribute PIONEER PIONEER-OLE severity difference reduction open-label this

that we Well, numbers to we're these as Cohort the we I on mind thoughts some terms of mind we the that previous collecting drug patient. the to seeing here study. are in comparisons can first reduction not Marc baseline measurements Phase in therapy characteristics - too, let me think to in PIONEER-HCM, get did relative in low and vary maybe the of keep question, level enough in keep to But the that II from mean, is patient B of know have study, I

most clinical that I properly dosing in seeing important anything these today. those obvious, Jeff, to patients, obstruction be the had the small referring So to think, patients. you're previous elimination still talked our and we due Marc, majority the part measures residual of to, that? we're May which other effect a we we've numbers in of add the of here, notably that measurements all study, that is the and in to feel we're fact the the the about of obstruction, that despite vast of

Jeff, effect was what's it's hence of concentration that we've on combination using A right that's more all -- basis. an ejection of the it's in the the doses learned Cohort fraction. about not. effective. getting OLE found We're left it's really rid Really to the ventricular Cohort and from What it B get individualized over-affecting needed without We've and to gradients the out. patients universally

think you in different do would and at results how weeks XX? week by like then X, impacted schedule long-term And EXPLORER dosing the be beyond adjustment X Great.

EXPLORER range. to Phase the optimal to II on comfortable is with we what very them in that, concentration think approach the we and because history single from studies, knew adjustment we more And I be their these get patients them determined have Yeah, Jeff, consistent. the previous were with to had a

us they emphasizes the to to, it dose to have with the two so do patients, a need only clinicians stepping the the ultimately going In XX and have that, as things: X-milligram world. So get referring by I X-milligram will everybody milligrams, start to we inch happen place come doing if study, safety, it real with to the in and you're We'll EXPLORER an two adjustments, need therapy. when is on This over we them that that is we up residual starting understand through how the two and we'll take we they it echo but once. then going use increments is in and X think, same if and into way really place this don't you history how adjusting up, do to second expect are do we're obstruction. stages, if we're mavacamten a approved these back in

don't with muscle folks of drug the we to zone in into of be is that goal is we to different. any optimal of end share So these see types this think the you get the Really, going to exposure results today. cardiac

Thanks.

you. Thank

Wells Birchenough with Fargo. question comes from next Our Jim

open. Your line is

the A patients Hi, missed comments, it of XX I've prepared how the guys. EXPLORER of response? questions. met but the apologize many Congrats definition I as in on updated few results. the

to of it. Jim, one, we the leads But peak data for us in were haven't answer measure we've VOX. all outlined today because patients this these been that to that on here hard robustly improved to having peak measured So VOX really we

have seeing functional class. So Heart X answer specifically of the in peak But analysis VOX. New element we patients does can't X York are Association we change out that these of XX responder of given an have unit

least hitting responder XX% at it. at the that analysis you're of looking So half

in And to or have that less are enroll then patients the inform anything what that might just is responses define robust seeing less EXPLORER in there features optimally study, you're versus patients better response? that responses there that a robust certain

Yes.

data are Jim, the here, consistently in that we're the think responses seeing I robust. pretty

So look they these are patients on really that doing well to be the drug.

bit So inclusion/exclusion with not reassures a seeing just or worth patients' of XX are and We're which right our inform little months patient a us to duration longest has obvious XX about data, over. for anything that, been ones. EXPLORER the in XX criteria that the really here

to that. echo add it's Taylor. would just Jim, Yes, I

reduction single XX, had ejection provoked patient single gradient had XX, every actually, every below maintained So had and patient a in below reduction think fraction I every in an gradient a XX%. above XX, resting below patient single

was consistent. it really So

Right. And just that at OLE. EXPLORER criteria of would patients all I these entry the add the met of time entry into

size in effect reduction a is atrial AFib then volume is EXPLORER numbers patient the and to say, put the left Marc, when question do study just the just AFib if not altogether, enough reduce it in you EXPLORER on could one and risk expected or rate a the baseline see translating that? big AFib to in volume. show we atrial effect in that potential left Can sufficient the risk, you think you final such And just remodeling maybe

left I volume where in this EXPLORER. at mean, risk, carefully we'll that's Well, looking be factors reduction AFib terms I atrial in the in mean, like of

In we to of a patients terms not look an be burden, the in may enough at burden, in and their going that to be actual we'll atrial in see yes, variability initial and but high powered there's AFib that. too, reduction fibrillation coming

required might adequacy when get clarity work additional from And approval some Thanks. or just one on Europe? EMA you of for a regulatory final, that EXPLORER from standpoint, be might in

we our Jim, continue with to in get interactions EMA. clarity

markets. for marrying a move our I closer think as introducing publicly to we that likely we'll strategy update view and with therapy down the clear on in EXPLORER those results

for tuned stay So that.

Thanks for taking the questions.

Thanks, Jim.

Thank you.

next Lynch. question Our Tazeen of America from Merrill Bank with comes Ahmad

line Your is open.

taking for Good my question. guys. morning, Thanks Hey.

questions data pretty much been have I all my answered. think today's on

you data obstructive, Based you presenting intend data expect? potential of can data from the should later ahead, we on updated any can year. you us that what on talk later non-obstructive have So this you've remind year? for throughs just about that plans looking do seen And you this read

Tazeen. Thanks, Yes.

about happening the our data is the So in a thinking in data share separately, of other second coming and year study just recall, doesn't MYK-XXX, the as enough, the of excited II of to specifically Phase or opposite of half which to Phase in in mavacamten, heart the terms the was that nonobstructed. that II where from target MAVERICK all consequences year we're for disease hypercontractility it's you the here later this clinical is whether underlying of designed in patients of what's the obstructed designed But may HCM. drives MAVERICK, contract HCM, quite

And disease of bodes surrogate which so disease, is for potential especially component the and the through diastolic well read compliance. parameters, the in we're really in prime, we're is for may burden of reduction today encouraged a driven E/e' most by seeing whose pressure, in differently for for that what a number patient be different primarily filling by that reasons, HCM notably, the non-obstructive diastolic improvements non-obstructive relaxation

to give in HCM more in that that's us seeing overall we're continues biomarkers underlying MAVERICK the of and exciting data the and path a believe have drivers forward to the HCM. tells all us of fact yes, that we're reason at for us our nonobstructed in confidence getting we of these So disease, lot the for concordance nonobstructed and really

So proper core future a tolerability, as for would which identify study, PIONEER, and safety function towards is we and dose-ranging few things, parameters. we well studies, which symptoms the in really its in MAVERICK at look trends successful dosing for it shows safety study, and improvements demonstrate improvements as a diastolic like a

classification, Association fraction, cetera. York we've things about the talked in like that of E/e' prime, to with half measurements the New here expect the second share are ejection today we Heart measurements you so et And NT-proBNP, year,

opportunity? Thanks. you XXX, that once other be given partnerships for for considering looking that of program data, for present just size Okay. would then potential And the you the

potential data hand we're to the be control, and where the and of under about excited in we back far future directions we're the our XXX understand is and optimal half have data, super here. for XXX. have want so to able so busy Program's track second been to which really is MAD compelling, on the re-evaluating So busy and we

something to by X systolic reiterate comprised suffer dysfunction, are that's there million Americans approximately to that's subgroups. believe group you're several and here, who Just we distinct from alluding a

that potential and that feel are indications is do there we're potential upcoming to the hopeful a can provide going XXX support further benefit, we number of So that data that.

our therapy. Our the development precision smaller subsets calls for approach for of patient identifying

bit in as I referenced. we to as to have and potential do that though opportunities make say to to exist you path, about the end with so to a this large our year. for got that's and going to how could want want for that, we've us, release own really think XXX parallel, that evaluating agent share out about we the will population, up in to those forward we development a data we we best-in-class believe targeted and opportunities and be been little move want later whether a we partnership that is come XXX framing on a partnering closer therapy So we understand has sure a more

we've the opportunity got that value therapy that way of end the being best it So XXX. precision is maybe a And partnership could be for development. possible the to up course, maximize better of suited ACT-X

we'll evaluating and the on on later have year. of tuned that, We're stay all this focus some So sharper in this.

you. Thank

you. Thank

Our next Citi. with question comes from Mohit Bansal

open. line Your is

question Thank VOX have a then you in One [ph] on morning. report my for I I is taking early question. your know good Very and it follow-up. peak super

more peak you yet, you at you a maybe you confirm have it when at the VOX time can and that later didn't ACC point, data? just on So clarity measure present will

Yes, Hi, peak Mohit. not of VOX is protocol. part this

very protocol relatively wanted and study, study in were up really who we that running it Just this back experienced for patients get them on it wanted of PIONEER make this positive effect PIONEER. in We drug. get quickly who really, to to and a we -- straightforward

and off of of to them keep to back have the was obligation some drug sense therapy. months, to of patients XX to them really out our driven for been So sites the X and it on

lean as it as keep possible. to tried we So

now is PIONEER-OLE. in have there no protocol current right plans for peak so to And VOX the

team. joining Got helpful. is the for it. And question Very then on second William, congrats

market And is you be just worked my as now payers can the developing? PAH the us done you here? what value as market understand that medicine to in versus the it on of understand Thank help much can Actelion, the you So have question similarities so this you. as well doctors is see help

for the I'm are learning for we experienced developed lot HCM between market Good around a of what the morning. hypertension. the and Thanks pulmonary arterial question. what I similarities, I think, marketplace as There

market this in is, them similarities. PAH - of treated the it's think obstructive market, is I than a that much and there order XXX,XXX a treated. patients with larger only a are cardiomyopathy some It's the dissimilarity much close with hypertrophic to one but of fifth magnitude larger being

I still sure. There from accurate doctors getting this some X about that getting treated. the be my think research X accurate patients known seem are and sense was when been many, being lack We for a of time, payers did the underdiagnosed before that payer some And awareness what they're here has fact, an an is, market, and even undertreated. can advocacy diagnosis, information met and the lot for is think, striking even they're disease importance last diagnosis. do HCM. about And to how or we getting many is patients the education though can suggest we treating should the of matter to patient that the that X payers it there seeing misdiagnosed, misleading that doing some then are me advocates a of a as around week with community, HCM be they're of with they quite I or

call So I nascent I think this market. less is this a more -- or a

payers the company, all improve the the and think the the the MyoKardia, education stakeholders, a HCPs, has patient of opportunity community. terrific to I

much. very you Thank Helpful.

Thank you.

with Fitzgerald. Our Cantor Alethia next from question Young comes

Your line is open.

this comment by I of Hi. know is some for dosing on that the you don't Thanks help in baseline so trends trials? that This on think dosing ongoing question. broadly either on could responses update characteristics much Alethia. you responses for the about if saw that could and you taking or Eileen saw us

a bit Sure. is give that. I'll just Taylor. This information little you of on

up at to So on distribution. dose, was study went had the X X stayed that and XX in the the expected XX, X think patients we I about that X-milligram

got we perspective. concentration also exposure We where expected to on and a

the talked as each out for that's dosing about consistency and modeled the terms all of we've as had before at of that then reduction, we response generated favorable doses appropriate really So had what in and expected preservation those EF the changes. we gradient patient, biomarker played

-- really here dose and get the it So the the right answer is, -- patients respond. point here to the they

Thank you so much.

Eileen. Thanks,

Thank you.

Markets. next with BMO Our Capital question from comes George Farmer

open. Your is line

and this taking on measurements, all correlating in Hi. handle there throughout? PK a maybe both but EXPLORER Thanks them in question once question. change of patients trial, the you dosing to least to the think I hit and get at the last unpractical -- over dose to the they're figure with some going particular level, label better open are in titration? follow patient the the stay you about And for want will on dose or time up to Do they titration.

talk question. blood will in second we measuring half be And question that well. the OLE, George, your as thanks yes, to are to good Hi, you, your and to we answer and levels it's doing the of for the is,

doing are in the We that study. EXPLORER

might those of a dose we've at that that But time might if chronic we've we're got on, need and level, focused require patients a necessarily dosing to think is question So duration we the up see that to to for be a compare bit our this. to more reduce and type a would there I might obstructed on the drug, be there to set at we're dose make in the were long we're to in in maintenance on for in to look to our points eye exposures one, the on exposures, in drug have our it, if where would scenario at. where reduction see actually all, a and what remodeling, those and look one will but the about and probably an over particularly do the the seeing by might for, And measurements I eye see say, it be the fantastic need we a levels one interesting But able programs terms that little scenario the a we think might run, you of of say it's be we it seeing positive only seen dose. is if do and haven't where animals hypothetical, let's that this might we will would driver long reduce maintenance dose we something of seen remodeling way, heart. dose it, or sense be we the positive reduction scenario we're that in taking. need

how what think question, then in think a something that more Okay, kind shift drives going of great. And it handicapping criteria the there EXPLORER about Is in should placebo patients? that on success? -- there, one is and you when do NYHA just broad we

and really but III, IV. from consistent let class maintaining Marc point study, a class as to, of will say, I I, alluded I'll address focused, let's view, in that framework clinician that EXPLORER and, class Yes, for our are June to say a field II, a class we

things in the a relates with with in two. of you consistency, know, New seeing consistently field how your between to that between class and to that York our of class ensure perspective? shown class clinical been to we're but looking at if And consistency, from things investigators class the today's But see encouraging we've those III, in imagine, a lot also asymptomatic to variability it conversation, II Association studies we're a as we're and of drive more a I, Marc, We have discriminate this has reduce those types bit and the as add studies that's alluded Heart in as I and well. so you doing lot to might lot

class have after kilo level improvement There responder New of improvements as they a how subjective well. seen that a have placebo And peak the to or the symptoms of and we above or but because and is improve by their to have patients if may still think, being VOX to for of greater you daily with the one that do. that clinician have patients in living, Sure. in Heart activities EXPLORER, X.X York NYHA VOX I milliliters criterion interfere you what classes, with you definition consistently minute is included that's why a assessment peak per able in we've per Association is not discussing somewhat the it may the of variability X.X,

Thanks Great. congregations. and very much

George. Thanks,

for I'd And you. showing further like no Gianakakos Tassos Thank call turn I'm closing back at the this questions time. to over remarks. to

about to from of second open-label look well the Shannon. incredibly share an the extension, growing first which the driving the our precision for of potential PIONEER our MAVERICK design years it's we're and II XX-month got of The consistent We've EXPLORER the commercialization our we we're forward of towards and as you portfolio huge objectives against time from and We today. compelling accomplished the rest time studies data since a from here X half the across organization, and our sharing with advancing data well-considered formation. from cardiac in talked both fuel a mavacamten our trial record for of track segments mavacamten. year in of executing a our our PIONEER XXX and vital Thanks, Phase this and entire muscle Well, data, our great diseases. amount product, have portfolio in MyoKardia. and confidence for in to This

experience are to goal HCM the indications and bringing leverage We committed growing of dysfunction to and additional diseases our and of treatment robust the through driver underlying our our with systolic programs. precision motivated mavacamten, capabilities R&D address of first and portfolio forth targeting diastolic and of our to specifically

here growing keeping and momentum So forward another we year the strong expect execution you a way. XXXX, of to year in updated along strong of progress look and

support all who achievements. are grateful whose mission Thanks and our your responsible the time are participate very to the share we and everybody dedicated for we to patients your our studies, our always, for today of investigators who of and employees for mission. continued our As to MyoKardia in

day. Have conference. Ladies your for wonderful Thanks today's this and concludes participation. gentlemen, a